Navigation Links
Simpler Anemia Treatment May Help Kidney Patients

Newer drug is given just once per month, experts say

FRIDAY, Oct. 19 (HealthDay News) -- A new approach for treating anemia in patients with severe kidney disease could help improve patients' quality of life, according to a U.S. study.

Compared with conventional therapy, giving patients an anti-anemia drug as infrequently as once a month could simplify anemia management, concluded Dr. Nathan Levin, of the Renal Research Institute in New York, and colleagues.

The findings are published in the Oct. 20 issue of The Lancet.

Conventional therapy with epoetin (a synthetic form of human erythropoietin that promotes red blood cell production) requires frequent administrations (at least once weekly), changes of dose, and close monitoring of hemoglobin concentrations.

In this study involving patients on dialysis, the researchers compared the use of a long-acting erythropoieses-stimulating agent variant of epoetin (methoxy polyethylene glycol-epoetin beta) given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week.

All 673 patients in the study received conventional epoetin treatment for the first four weeks of the study. After that, one group of patients received methoxy polyethylene glycol-epoetin beta every two weeks, another group received methoxy polyethylene glycol-epoetin beta every four weeks, and the third group continued receiving conventional epoetin treatment.

After about 42 weeks, there were no statistically significant differences in hemoglobin concentrations between the three groups. Based on their findings, the researchers recommended that methoxy polyethylene glycol-epoetin beta be introduced as an option for simplified management of anemia in patients on dialysis.

However, the authors of an accompanying Comment article called for more research.

"Before we can concur on a precise clinical role for this molecule, we need to explore issues other than simply the non-inferiority with other epoetins to reach certain unvalidated surrogates. Different doses and molecular characteristics of epoetins may affect patient-level endpoints, independent of achieved hemoglobin. When these issues are examined, we might be truly confident that a newer molecule is non-inferior to existing ones," wrote Dr. Rowan Walker of the Royal Melbourne Hospital and Monash University Alfred Hospital in Melbourne, Australia, and Dr. Giovanni Strippoli, of the University of Sydney, Australia, and the Mario Negri Sud Consortium in Chieti, Italy.

More information

The U.S. National Institute on Diabetes and Digestive and Kidney Diseases has more about anemia.

-- Robert Preidt

SOURCE: The Lancet, news release, Oct. 19, 2007

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Surgeons Develop Simpler Way to Cure Atrial Fibrillation
2. Detection of Malignant Breast Tumors Made Simpler and More Effective
3. Liver Regeneration may Be Simpler Than Previously Thought
4. Fight anemia by fortifying crops with iron!!!!!!!!
5. Doctors advice early anemia tests
6. Anemia Treatment for Cancer Patients
7. Anemia Treatment for Cancer Patients
8. Anemia Treatment for Cancer Patients Might Not be a Good Idea.
9. Anemia may Lead to Physical Decline
10. Gene to identify risk of stroke in sickle cell anemia
11. New treatment for babies with sickle cell anemia
Post Your Comments:
(Date:11/26/2015)... , ... November 26, 2015 , ... Indosoft Inc., developer ... of an application server to improve system efficiency and reliability. , The new Q-Suite ... of these standards, the system avoids locking itself into a specific piece of software ...
(Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
Breaking Medicine Technology: